Ownership and insider activity for Artiva Biotherapeutics, Inc. (ARTV): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy.
Price
| Price | $8.60 |
| Market Cap | $420M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-15 | Aslan Fred | A-Award | 110,000 | |
| 2026-09-15 | Aslan Fred | A-Award | 315,000 | $2.8M |
| 2026-09-10 | Aslan Fred | A-Award | 45,000 | |
| 2026-09-10 | Aslan Fred | A-Award | 155,000 | $1.6M |
| 2026-09-10 | RA CAPITAL MANAGEMENT, L.P. | A-Award | 16,250 | $169K |
| 2026-09-10 | Stoppel Laura | A-Award | 16,250 | $169K |
| 2026-09-10 | Sorg Elaine K. | A-Award | 16,250 | $169K |
| 2026-09-10 | HOUGEN ELIZABETH L | A-Award | 16,250 | $169K |
| 2026-09-10 | DANIELS BRIAN | A-Award | 16,250 | $169K |
| 2026-09-10 | Baker Daniel G. | A-Award | 16,250 | $169K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.9M | $25.4M | $160.9M | $102.5M | $53.5M | $40.2M | $26.7M |
| Short-term Investments | 0 | 0 | 0 | 0 | $23.5M | $145.2M | $81.3M |
| Receivables | 0 | 0 | $468000 | $525000 | $1.8M | $146000 | $767000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $2.0M | $26.1M | $162.3M | $104.7M | $79.8M | $188.6M | $112.7M |
| Property, Plant & Equipment | $2.5M | $2.4M | $4.1M | $27.6M | $24.6M | $20.4M | $17.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $4.8M | $29.2M | $169.9M | $133.1M | $105.1M | $209.6M | $130.9M |
| Accounts Payable | $258000 | $2.2M | $1.4M | $1.1M | $614000 | $1.1M | $355000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $3.1M |
| Total Current Liabilities | $942000 | $5.8M | $19.3M | $25.6M | $12.2M | $12.3M | $13.1M |
| Long-term Debt | $5.6M | 0 | 0 | 0 | 0 | 0 | $7.9M |
| Total Liabilities | $8.8M | $50.8M | $258.8M | $273.8M | $267.1M | $22.9M | $21.0M |
| Retained Earnings | -$4.0M | -$22.0M | -$93.8M | -$152.6M | -$181.3M | -$246.7M | -$330.5M |
| Total Equity | -$4.0M | -$21.6M | -$88.9M | -$140.7M | -$162.0M | $186.6M | $110.0M |
| Total Debt | $7.8M | $2.1M | $1.7M | $19.4M | $16.9M | $14.4M | $10.9M |
| Net Debt | $5.9M | -$23.3M | -$159.2M | -$83.1M | -$60.1M | -$171.1M | -$97.1M |
| Working Capital | $1.0M | $20.3M | $143.0M | $79.0M | $67.6M | $176.4M | $99.6M |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 24.16 |
Profitability
| Return on Equity | -53.86% |
| Return on Invested Capital | -26.91% |
| Return on Assets | -24.64% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADVM · ALXO · CNTB · DTIL · GUTS · IFRX · MGX
Explore sector: Healthcare · Biotechnology
More sections of ARTV: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks